BINOSTO

This brand name is authorized in United States. It is also authorized in Cyprus, Estonia, Finland, Germany, Ireland, Israel, Malta, Romania, Singapore, UK.

Active ingredients

The drug BINOSTO contains one active pharmaceutical ingredient (API):

1	Alendronate sodium trihydrate UNII 2UY4M2U3RA - ALENDRONATE SODIUM
	Alendronic acid is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation. The bone formed during treatment with alendronic acid is of normal quality.
	Read more about Alendronic acid

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BINOSTO Effervescent tablet	MPI, EU: SmPC	Marketing Authorisation Holder

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M05BA04	Alendronic acid	M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BA Bisphosphonates
Discover more medicines within M05BA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	12592537, 12592543
EE	Ravimiamet	1647604, 1647615
FI	Lääkealan turvallisuus- ja kehittämiskeskus	529117
GB	Medicines & Healthcare Products Regulatory Agency	303174, 381207, 391001
IE	Health Products Regulatory Authority	37011
IL	מִשְׂרַד הַבְּרִיאוּת	8054
MT	Medicines Authority	AA1173/06801
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W63265001, W63265002, W63265003
SG	Health Sciences Authority	15268P
US	FDA, National Drug Code	17139-400